What is Zacks Research’s Forecast for BDX FY2027 Earnings?

Becton, Dickinson and Company (NYSE:BDX) – Stock analysts at Zacks Research dropped their FY2027 earnings per share estimates for shares of Becton, Dickinson and Company in a research report issued to clients and investors on Monday, December 16th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings per share of $16.68 for the year, down from their previous estimate of $16.75. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share.

A number of other analysts have also recently weighed in on BDX. Evercore ISI raised their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $283.50.

Becton, Dickinson and Company Stock Down 0.8 %

Shares of NYSE BDX opened at $225.68 on Wednesday. The business has a 50-day moving average of $230.57 and a two-hundred day moving average of $233.40. The company has a market capitalization of $65.25 billion, a price-to-earnings ratio of 37.99, a price-to-earnings-growth ratio of 1.64 and a beta of 0.41. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $249.89. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.42 EPS.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a yield of 1.84%. Becton, Dickinson and Company’s payout ratio is currently 70.03%.

Insider Activity

In related news, EVP Roland Goette sold 4,483 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the transaction, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This represents a 15.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BDX. Arete Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $767,000. Charles Schwab Investment Management Inc. increased its holdings in Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after buying an additional 1,317,723 shares in the last quarter. Nomura Asset Management Co. Ltd. increased its holdings in Becton, Dickinson and Company by 2.3% in the third quarter. Nomura Asset Management Co. Ltd. now owns 561,040 shares of the medical instruments supplier’s stock valued at $135,267,000 after buying an additional 12,845 shares in the last quarter. Benson Investment Management Company Inc. lifted its position in shares of Becton, Dickinson and Company by 13.2% during the 3rd quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock valued at $5,380,000 after acquiring an additional 2,602 shares during the period. Finally, Swedbank AB boosted its stake in shares of Becton, Dickinson and Company by 1.8% during the 3rd quarter. Swedbank AB now owns 150,838 shares of the medical instruments supplier’s stock worth $36,367,000 after acquiring an additional 2,729 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.